| 19.45 0.25 (1.3%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.43 | 1-year : | 26.1 |
| Resists | First : | 20.92 | Second : | 22.35 |
| Pivot price | 20.17  |
|||
| Supports | First : | 18.61 | Second : | 15.48 |
| MAs | MA(5) : | 19.15 |
MA(20) : | 20.48 |
| MA(100) : | 24.37 |
MA(250) : | 24.49 |
|
| MACD | MACD : | -0.9  |
Signal : | -0.8 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 9.2 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 30.52 | Low : | 18.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VCYT ] has closed above bottom band by 28.1%. Bollinger Bands are 4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.55 - 19.65 | 19.65 - 19.73 |
| Low: | 18.79 - 18.9 | 18.9 - 19 |
| Close: | 19.27 - 19.45 | 19.45 - 19.61 |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Thu, 18 Apr 2024
Sumitomo Mitsui Trust Holdings Inc. Cuts Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Tue, 16 Apr 2024
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will ... - Business Wire
Mon, 15 Apr 2024
Veracyte (NASDAQ:VCYT) Sets New 1-Year Low on Analyst Downgrade - MarketBeat
Mon, 26 Feb 2024
Veracyte, Inc. (NASDAQ:VCYT): Is Breakeven Near? - Simply Wall St
Fri, 23 Feb 2024
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript February 22, 2024 - Yahoo Finance
Thu, 22 Feb 2024
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 101 (%) |
| Shares Short | 2,460 (K) |
| Shares Short P.Month | 2,510 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.43 |
| Profit Margin | -14.6 % |
| Operating Margin | -2.3 % |
| Return on Assets (ttm) | -1.3 % |
| Return on Equity (ttm) | -4.8 % |
| Qtrly Rev. Growth | 19.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.69 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 38 (M) |
| Levered Free Cash Flow | 34 (M) |
| PE Ratio | -28.19 |
| PEG Ratio | 0 |
| Price to Book value | 1.34 |
| Price to Sales | 4.13 |
| Price to Cash Flow | 36.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|